Purchase this article with an account.
H. Ruiz-Garcia, R. Velez-Montoya, O. Ustariz-Gonzalez, M. Gordon-Angelozzi, G. Garcia-Aguirre, M. E. Torres-Soriano, V. Kon-Jara, J. L. Guerrero-Naranjo, H. Quiroz-Mercado; Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous, Blood and Subretinal Fluid in Patients With Stage V Retinopathy of Prematurity. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3877.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To measure the levels of vascular endothelial growth factor (VEGF) in aqueous, vitreous and subretinal fluid (SRF) in patients with stage V retinopathy of prematurity (ROP).
The study was approved by the hospital ethics board and was performed according to the tenets of the declaration of Helsinki. We included patients with history of prematurity (<32 weeks of gestation), low birth weight (<1500gr) and a clinical diagnosis of stage V ROP, who were scheduled for vitrectomy. We took samples of blood, aqueous, vitreous and SRF. The samples were then analysed by ELISA for Human VEGF. We also sampled the aqueous of healthy patients with clinical diagnosis of congenital cataracts as a control group. Statistical analyses were performed using SPSS Software, version 10.1.0 (Inc. SPSS Chicago, IL).
We included a total of 16 patients. The average gestational age was 29.56±2.80 weeks. The postconceptional age at the moment of the surgery was 20.94±16.62 months. All the patients had less than 1500gr birth weight of which 8 had less than 1250gr. Forty four percent of patients had an active ROP at the moment of surgery. The remaining 56% did not show activity. The average VEGF levels in aqueous samples were 85.03±61.42pg/ml. In the vitreous: 57.21±49.79pg/ml. In SRF: 1600.63±355.14pg/ml and in blood: 148.25±91.11pg/ml. The average aqueous VEGF level in the control group was 14.67±1.56. All the groups had statistically significant difference with the control group (p<0.001).
The results in this study show a dramatic increase in the levels of VEGF in all intraocular fluids. The treatment of this pathology with and anti-VEGF drug could be justified.
Clinical Trial: :
This PDF is available to Subscribers Only